Impact of p16 expression on surgical management of malignant melanoma and pancreatic carcinoma

American Journal of Surgery

Volumn 177, Issue 1, 1999, Pages 15-18

  Bullock, Gloria J ^a   Green, Judith L ^a   Baron, Paul L ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16;

ARTICLE; CANCER SURGERY; FAMILY HISTORY; GENE MUTATION; HUMAN; MEDICAL INFORMATION; MEDICAL LITERATURE; MELANOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MELANOMA; MUTATION; PANCREATIC NEOPLASMS; PROGNOSIS; RISK; SKIN NEOPLASMS;

EID: 0032986693     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(98)00297-9     Document Type: Article

References (39)

1. Serrano M., Hannon G.J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 366:1993;704-707.
2. Kamb A., Gruis N.A., Weaver-Feldhaus J., et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 264:1994;436-440.
3. Robinson W.A., Elefanty A.G., Hersey P. Expression of the tumour suppressor genes p15 and p16 in malignant melanoma. Melanoma Res. 6:1996;285-289.
4. INK4 mutations. NEJM. 333:1995;970-974.
5. Hussussian C.J., Struewing J.P., Goldstein A.M., et al. Germline p16 mutations in familial melanoma. Nature Genet. 8:1994;15-21.
6. Fountain J.W., Karayiorgou M., Ernstoff M.S., et al. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci USA. 89:1992;10557-10561.
7. Goldstein A.M., Dracopoli N.C., Ho E.C., et al. Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevus (CMM/DN) on chromosome 1p, and evidence for genetic heterozygosity. Am J Hum Genet. 52:1993;537-550.
8. Cannon-Albright L.A., Kamb A., Skolnick M. A reviewed of inherited predisoposition to melanoma. Semin Oncol. 23:1996;667-672.
9. Tucker MA, Halpern A, Holly EA, et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA. 1997;277:1439-144.
10. Seykora J., Elder D. Dysplastic nevi and other risk markers for melanoma. Semin Oncol. 23:1996;682-687.
11. Ohta M., Nagai H., Shimizu M., et al. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res. 54:1994;5269-5272.
12. Platz A., Ringborg U., Lagerlof B., et al. Mutational analysis of the CDKN2 gene in metastases from patients with cutaneous malignant melanoma. Br J Cancer. 73:1996;344-348.
13. Monzon J., Liu L., Brill H., et al. CDKN2A mutations in multiple primary melanomas. NEJM. 338:1998;879-887.
14. Goldstein A.M., Tucker M.A. Screening for CDKN2A mutations in hereditary melanoma. J Natl Cancer Inst. 89:1997;676-677.
15. Whelan A.J., Bartsch D., Goodfellow P.J. Brief report a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene . NEJM. 333:1995;975-977.
16. Grunis N.A., van der Velden P.A., Sandkujiol L.A., et al. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nature Genet. 10:1995;351-353.
17. Platz A., Hansson J., Mansson-Brahme E., et al. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families. J Natl Cancer Inst. 89:1997;697-702.
18. Urrutia R., DiMagno E.P. Genetic markers the key to early diagnosis and improved survival in pancreatic cancer? Gastroenterology. 110:1996;306-310.
19. Hahn S.A., Kern S.D. Molecular genetics of exocrine pancreatic neoplasms. Surg Clin North Am. 75:1995;857-868.
20. Naumann N., Savitskaia N., Eilert C., et al. Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Gastroenterology. 1104:1996;1215-1224.
21. Huang L., Goodrow T.L., Zhang S.Y., et al. Deletion and mutational analyses of the p16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveal a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. Cancer Res. 565:1996;1137-1141.
22. Bartsch D., Shevlin D.W., Tung W.S., et al. Frequent mutations of CDKN2 in primary pancreatic adenocarcinoma. Gene Chromosome Cancer. 143:1995;189-195.
23. Caldas C., Hahn S.A., da Costa L.T., et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet. 8:1994;27-32.
24. Ahlgren J.D. Epidemiology and risk factors in pancreatic cancer. Semin Oncol. 23:1996;241-250.
25. Lynch H.T., Smyrk T., Kern S.E., et al. Familial pancreatic cancer a review . Semin Oncol. 23:1996;251-275.
26. Lynch H.T., Fitzsimmons M.L., Smyrk T.C., et al. Familial pancreatic cancer clinicopathologic study of 18 nuclear families . Am J Gastroenterol. 85:1990;54-60.
27. Ghadirian P., Boyle P., Simard A., et al. Reported family aggregation of pancreatic cancer within a population-based case-control study in the Francophone community in Montreal, Canada. Int J Pancreatol. 10:1991;183-196.
28. Price T.F., Payne R.L., Oberleitner M.G. Familial pancreatic cancer in South Louisiana. Cancer Nurs. 19:1996;275-282.
29. Ruggeri B.A., Huang L., Berger D., et al. Molecular pathology of primary and metastatic ductal pancreatic lesions analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions . Cancer. 79:1997;700-716.
30. Rozenblum E., Schutte M., Goggins M., et al. Tumor-suppressor pathways in pancreatic carcinoma. Cancer Res. 57:1997;1731-1734.
31. Matsumura Y., Yamagishi N., Miyakashi J., et al. Increase in radiation sensitivity of human malignant melanoma cells by expression of wild-type p16 gene. Cancer Lett. 115:1997;91-96.
32. INK4/MTS-1) gene in human melanoma cells relevance to tumor growth and metastasis. Oncogene. 11:1995;1399-1402.
33. Clurman B.E., Groudine M. The CDKN2A tumor-suppressor locus a tale of two proteins . NEJM. 338:1998;910-912.
34. INK4aallele. J Natl Cancer Inst. 88:1996;1489-1491.
35. Hintze R.E., Adler A., Veltzke W., et al. Clinical significance of magnetic resonance cholangiopancreatography (MRCP) compared to endoscopic retrograde cholangiopancreatography (ERCP). Endoscopy. 29:1997;182-187.
36. Wakabayashi T., Sawabu N., Watanabe H., et al. Detection of K-ras point mutation at codon 12 in pure pancreatic juice collected 3 years and 6 months before the clinical diagnosis of pancreatic cancer. Am J Gastroenterol. 91:1996;1848-1851.
37. Watanabe H., Miyagi C., Yamaguchi Y., et al. Detection of K-ras point mutations at codon 12 in pancreatic juice for the diagnosis of pancreatic cancer by hybridization protection assay a simple method for the determination of the types of point mutations . Jpn J Cancer Res. 87:1996;466-474.
38. Caldas C., Hahn S.A., Hruban R.H., et al. Detection of K-ras mutation in stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res. 54:1993;3568-3573.
39. Sorenson G.D., Pribish D.M., Valone F.H., et al. Soluble normal and mutated DNA sequences form single-copy genes in human blood. Cancer Epidemiol Biomark Prevent. 3:1994;67-71.